An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

SUMMARY

N/A

COH Protocol Number : 15121

ClinicalTrials.gov Number : NCT02368301

Principal Investigator : Htut, Myo M.D.

Sponsor : Bristol-Myers Squibb

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :